Abstract
To examine the responsiveness of GH secretion in patients with acromegaly, TRH (500 µg), arginine (0.5 g/kg BW), and LRH (100 µg) were administered to 15 patients with acromegaly. Ten of these patients responded to at least, one of the three agents and showed increases in their plasma GH levels 50% above basal values (categorized as group I). The remaining five patients, however, showed no response to any of these agents (categorized as group II). After the administration of somatostatin (500 ±g, iv, for 75 min), group I patients showed significantly greater decreases in plasma GH (−68.0 ± 4.3%) from the basal value than did group II (−34.2 ±1.8% P <0.001). CB-154 treatment was carried out n eight patients and was effective in group I(four of five patients) but not in group II (none of three patients). In addition, physiological fluctuations of plasma GH within 3 h were much greater in group I than in group II subjects. There were no differences, however, in blood glucose or plasma insulin responses to th...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
